Clinical trials: malaria
Uncomplicated Falciparum Malaria
Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children
Title: Efficacy and safety of artesunate-amodiaquine combined with methylene blue for falciparum malaria treatment in African children: randomised controlled trial.
- Trial name
- NCT01407887
- Testing
- artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)
- Where
- Burkina Faso
- Volunteers
- 180 people
- Sponsor
- Heidelberg University
Malaria, Malaria in Pregnancy
Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy
This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) plus dihydroartemisinin-piperaquine (DP) significantly reduces the risk of malaria infection (primary…
- Conditions
- Malaria, Malaria in Pregnancy, Pregnancy Related
- Trial name
- SAPOT (NCT05426434)
- Testing
- Dihydroartemisinin-Piperaquine (DP), Sulfadoxine pyrimethamine (SP)
- Where
- Papua New Guinea
- Volunteers
- 1,172 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Malaria,Falciparum
Cohort Event Monitoring Study of Pyramax®
The study is to be performed in public health facilities in Central and West Africa where Pyramax will be used as treatment of uncomplicated malaria episodes, including repeat episodes.
- Trial name
- NCT03201770
- Testing
- pyronaridine artesunate
- Where
- 5 sites in Cameroon, Côte d’Ivoire and 3 more
- Volunteers
- 8,572 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Malaria
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
This will be a double-blinded randomized controlled phase III trial of 782 HIV uninfected pregnant women and the children born to them.
- Trial name
- PROMOTE-BC3 (NCT02793622)
- Testing
- Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy, Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy
- Where
- Uganda
- Volunteers
- 782 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria, Falciparum
The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children
Children participating in a study evaluating the efficacy of chloroquine and amodiaquine for the treatment of malaria will, if getting malaria during follow-up, be re-treated with sulfadoxine-pyrimethamine (SP) in accordance with…
- Trial name
- NCT00137553
- Testing
- Sulfadoxine-pyrimethamine (Fansidar)
- Where
- Guinea-Bissau
- Volunteers
- 60 people
- Sponsor
- Bandim Health Project
Malaria
Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali
This study tested the safety of a new malaria vaccine in adults in Mali, West Africa, and measured the ability of the vaccine to stimulate antibodies directed against the malaria protein that the vaccine is based on.
- Trial name
- NCT00308061
- Testing
- FMP1/AS02A, Imovax Rabies Vaccine
- Where
- Mali
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine
The ongoing Malaria Vaccine Pilot Evaluation (MVPE) is being conducted in Ghana, Malawi and Kenya through community and sentinel hospital surveillance systems and a series of household surveys (to measure vaccine coverage).
- Trial name
- MVPE-CC (NCT05041556)
- Testing
- Case-control study of clinical outcomes, Case-control study of mortality outcome
- Where
- 4 sites in Ghana, Kenya and 1 more
- Volunteers
- 9,280 people
- Sponsor
- Kintampo Health Research Centre, Ghana
Malaria
Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)
This is an initial efficacy study of a candidate antimalarial in human subjects with uncomplicated malaria caused by the most common and most important parasite in Africa (Plasmodium falciparum).
- Trial name
- NCT01614964
- Testing
- AQ-13 Treatment, Coartem Treatment
- Where
- Mali
- Volunteers
- 66 people
- Sponsor
- Tulane University
Malaria
Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen
This study is being done to assess the possibility of the potential integration of malaria vaccine into the EPI regimen. It will evaluate whether the malaria vaccine is safe and immunogenic in infants aged 6 to 10 weeks at first…
- Trial name
- NCT00436007
- Testing
- GSK 257049, Tritanrix™ HepB/Hib, Rouvax™
- Where
- 3 sites in Gabon, Ghana and 1 more
- Volunteers
- 511 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria
The purpose of this study is to compare the efficacy of sulfadoxine-pyrimethamine plus artesunate with that of sulfadoxine-pyrimethamine on its own for the treatment of uncomplicated malaria.
- Trial name
- NCT00203736
- Testing
- Sulfadoxine-pyrimethamine, Artesunate plus sulfadoxine-pyrimethamine
- Where
- 2 sites in Mozambique
- Volunteers
- 240 people
- Sponsor
- University of Cape Town
Malaria
The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
Over one year period in an area with universal coverage of LLIN and ACT provision as the first-line treatment of malaria, the investigators intend to evaluate the impact of DL on malaria transmission as measured by the incidence…
- Trial name
- DL (NCT02533336)
- Testing
- abamectin and fenpyroximate
- Where
- Tanzania
- Volunteers
- 4,917 people
- Sponsor
- National Institute for Medical Research, Tanzania
Malaria
Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
The purpose of this observer-blind study is to gather key efficacy, safety, and immunogenicity information on GSK's candidate malaria vaccine in infants and children.
- Trial name
- NCT00866619
- Testing
- Malaria Vaccine 257049, Meningococcal C Conjugate Vaccine, Cell-culture rabies vaccine
- Where
- 10 sites in Burkina Faso, Gabon and 5 more
- Volunteers
- 15,459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers
A healthy volunteer study to characterise the exposure of the two study medications, following administration of OZ439 + TPGS granules with piperaquine phosphate granules (intended for children) and with piperaquine phosphate…
- Trial name
- NCT01958619
- Testing
- 1440mg PQP tablets, 960mg PQP tablets, 800mg OZ439 + TPGS
- Where
- United Kingdom
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia
The proportion of malaria that is the Plasmodium vivax species is increasing in Indonesia. Reducing vivax malaria will require innovative solutions to cure both the blood and liver stages of the disease.
- Trial name
- SCOPE (NCT05879224)
- Testing
- Revised case management package
- Where
- 6 sites in Indonesia
- Volunteers
- 2,999 people
- Sponsor
- Menzies School of Health Research
Malaria
Africa Ready Malaria Screening
This study aims to develop immuno-analytical assays for testing the titres of malaria antibodies in Ghanaian patients' and/or donors' sera using a recombinantly produced MSP119 fusion protein and/or MSP119-derived synthetic…
- Trial name
- ARMS (NCT06153862)
- Testing
- Immuno analytical assay
- Where
- Ghana
- Volunteers
- 1,640 people, healthy volunteers welcome
- Sponsor
- University of Ghana
Malaria
Factors Influencing Adoption of a Novel Malaria Treatment in Côte d'Ivoire, Ghana, and Rwanda
This non-interventional qualitative study will examine factors that influence the adoption of a novel malaria treatment in Côte d'Ivoire, Ghana, and Rwanda.
- Trial name
- NCT07896746
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Tropical Infectious Diseases
Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region
Severe malaria and bacterial Blood Stream Infections (bBSI) are impossible to differentiate clinically. This poses a particular threat in low resource areas, where bBSI is often not diagnosed due to the unavailability of rapid…
- Trial name
- PALUBAC (NCT02669823)
- Testing
- None, treatment as actual best practice
- Where
- Burkina Faso
- Volunteers
- 930 people
- Sponsor
- Sysmex Europe GmbH
Falciparum Malaria
Clinical Evaluation of Long-term Sequelae in Patients With Severe Plasmodium Falciparum Malaria
Malaria, endemic in 85 countries, remains a major concern. By 2022, there will be 249 million cases and 608,000 deaths, 94% of them in Africa.
- Trial name
- SMAEE (NCT06992297)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 56 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Malaria
P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a)
In the current randomized trial, the investigators will test the ability of two experimental approaches to malaria infection management to reduce malaria transmission potential.
- Trial name
- NCT03705624
- Testing
- Enhanced Community Case Management (CCM), Monthly Screening and Treatment (MSAT)
- Where
- Burkina Faso
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Malaria
Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks
Primary objective: to demonstrate the non-inferiority of PCR adjusted adequate clinical and parasitological response at D28 of artesunate + amiodaquine versus artemether + lumefantrine, based on the first malaria attack of each…
- Trial name
- NCT00540410
- Testing
- Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination), Coartem® (arthemether+ lumefantrine)
- Where
- Senegal
- Volunteers
- 366 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.